Mereo BioPharma Group plc (MREO) research

Mereo BioPharma Group plc
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$0.34
As of

Mereo BioPharma Group plc (MREO): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-19.

As of . Source: SEC EDGAR filings for MREO. Method and limitations.

SHARE THIS CARD

Share the MREO intelligence card

A branded snapshot of MREO: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion MREO intelligence card preview
Post to X
LIVE TERMINAL

See MREO live in the terminal

Track MREO's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live MREO terminal, free

Active signals for MREO

FREE, NO ACCOUNT

Every signal on MREO, as it fires

You are seeing 5 of 13 signals recorded on MREO since 2026-05-17.

The five above landed across 2 days. The other 8 were recorded on 2 other days. 10 of the 13 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in MREO (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 589492107 · 2026Q2$419K0.00%,
CITADEL ADVISORS LLCCUSIP 589492107 · 2026Q2$141K0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 589492107 · 2026Q2$17K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, MREO

MREO against its peers

MREO's operating margin of -8021.4% ranks in the 45th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.

MetricMREOPeer medianPercentilen
Revenue FY500000 USD465000 USD5010
Operating margin-8021.4%-6056.4%459
Net margin-8375.6%-5619.6%4110
Return on equity-102.4%-96.6%4518

Peers (24): ELOX, INMB, IMA, SER, IBO, DWTX, HRTX, ELTX, EXOZ, XLO, PDSB, TIL, IMMP, CALC, HYPD, BOLD, TVGN, HOWL, IBIO, AURX, INKT, LONA, XBIT, GRCE. Left out: HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (MREO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more MREO signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MREOand get the insider, 13F, options, and confluence read in one view.

Open the live MREO terminal, free